| Literature DB >> 31057723 |
Heba Takleef Majeed1, Ahmed Abduljabbar Jaloob Aljanaby1.
Abstract
BACKGROUND: Urinary Tract Infection (UTI) in patients with Chronic Kidney Disease (CKD) caused by multi-drug resistance and Extended Spectrum Beta Lactamase (ESBL)-producing gram-negative bacteria has been increased in different countries. The aim of the present study was to detect the antibiotic susceptibility patterns and the distribution of Bla-TEM, Bla-SHV and Bla-CTX-M genes in gram-negative bacteria isolated from outpatients infected with UTI, with and without CKD in Al-Najaf city, Iraq.Entities:
Keywords: Chronic kidney disease; Iraq; SHV; TEM; Urinary tract infections
Year: 2019 PMID: 31057723 PMCID: PMC6490404
Source DB: PubMed Journal: Avicenna J Med Biotechnol ISSN: 2008-2835
Primers sequences of three genes used in this study
| F:CAGCGGTAAGATCCTTGAGA | 643 | ||
| R:ACTCCCCGTCGTGTAGATAA | |||
| F:GGCCGCGTAGGCATGATAGA | 714 | Ensor | |
| R:CCCGGCGATTTGCTGATTTC | |||
| F:AACCGTCACGCTGTTGTTAG | 766 | ||
| R:TTGAGGCGTGGTGAAGTAAG |
Thermo cycle conditions of three genes used in this study
| 95 | 94 | 52 | 72 | 30 | 72 | Ensor | |
| 95 | 94 | 55 | 72 | 30 | 72 | ||
| 95 | 94 | 57 | 72 | 30 | 72 | ||
Figure 1.Distribution of 120 outpatients infected with urinary tract infection according to gender. WKD: Without kidney disease, CKD: Chronic kidney disease.
Distribution of 120 outpatients infected with urinary tract infection according to age groups
| 3 (5) | 4 (6.6) | 7 (5.8) | |
| 7 (11.7) | 5 (8.3) | 12 (10) | |
| 10 (16.7) | 7 (11.7) | 17 (14.2) | |
| 14 (23.3) | 16 (26.7) | 30 (25) | |
| 22 (36.6) | 26 (43.3) | 48 (40) | |
| 4 (6.7) | 2 (3.3) | 6 (5) | |
| 60 (100) | 60 (100) | 120 (100) |
WKD: Without kidney disease, CKD: Chronic kidney disease.
Figure 2.Numbers and percentages of gram-negative bacteria isolated from 120 urine samples of outpatients infected with urinary tract infection.
Figure 3.Gram-negative bacteria on CHROMagar surface after 24 hr of incubation at 37°C isolated from urine of outpatients infected with urinary tract infection. 1- K. pneumoniae 2- P. aeruginosa 3- Proteus 4- E. coli 5- C. freundii 6- E. aerogenes.
Numbers and percentages of gram-negative bacterial isolates from 120 urine samples of outpatients infected with urinary tract infection according to gender
| 9 | 20 | 29 (48.3) | 7 | 10+3 | 20 (30.3) | 49(38.9) | |
| 6 | 12 | 18 (30) | 5 | 9+3 | 17 (25.8) | 35(27.8) | |
| 3 | 5 | 8 (13.3) | 3 | 7 | 10 (15.2) | 18(14.3) | |
| 0 | 3 | 3 (5) | 3 | 6 | 9 (13.7) | 12(9.5) | |
| 0 | 2 | 2 (3.4) | 1 | 5 | 6 (9) | 8(6.3) | |
| 0 | 0 | 0 (0.0) | 0 | 4 | 4 (6) | 4(3.2) | |
| 18 | 42 | 60 (100) | 19 | 47 | 66 (100) | 126(100) | |
WKD: Without kidney disease, CKD: Chronic kidney disease,
= Mixed growth
Antimicrobials sensitivity test of 126 gram-negative bacterial isolates from urine of outpatients infected with urinary tract infection
| 10(20.4) | 0(0.0) | 39(79.6) | 5(14.2) | 0(0.0) | 30(85.8) | 0(0.0) | 0(0.0) | 18(100) | |
| 23(46.9) | 2(4) | 24(49.1) | 9(25.8) | 0(0.0) | 26(74.2) | 8(44.5) | 0(0.0) | 10(55.5) | |
| 28(57.2) | 0(0.0) | 21(42.8) | 15(42.8) | 0(0.0) | 20(57.2) | 10(55.5) | 0(0.0) | 8(44.5) | |
| 27(55.1) | 0(0.0) | 22(44.9) | 12(34.3) | 0(0.0) | 23(65.7) | 10(55.5) | 0(0.0) | 8(44.5) | |
| 24(48.9) | 3(6.2) | 22 (44.9) | 14(40) | 0(0.0) | 21(60) | 9(50) | 0(0.0) | 9(50) | |
| 49(100) | 0(0.0) | 0(0.0) | 33(94.3) | 0(0.0) | 2(5.7) | 18(100) | 0(0.0) | 0(0.0) | |
| 31(63.3) | 0(0.0) | 18(36.7) | 14(40) | 2(5.7) | 19(54.3) | 11(61.3) | 0(0.0) | 7(38.7) | |
| 35(71.5) | 0(0.0) | 14(28.5) | 23(65.7) | 3(8.5) | 9(25.8) | 13(72.3) | 0(0.0) | 5(27.7) | |
| 34(69.4) | 0(0.0) | 15(30.6) | 23(65.7) | 0(0.0) | 12(34.3) | 9(50) | 0(0.0) | 9(50) | |
| 30(61.3) | 0(0.0) | 19(38.7) | 17(48.5) | 0(0.0) | 18(51.5) | 10(55.5) | 0(0.0) | 8(44.5) | |
| 34(69.3) | 0(0.0) | 15(30.6) | 19(54.3) | 0(0.0) | 16(45.7) | 11(61.3) | 0(0.0) | 7(38.7) | |
| 31(63.3) | 0(0.0) | 18(36.7) | 21(60) | 0(0.0) | 14(40) | 11(61.3) | 0(0.0) | 7(38.7) | |
AB: Antibiotics, S: Sensitive, I: Intermediate, R: Resistance, AX: Amoxicillin 25 μg , AMC: Amoxicillin + Clavulanic acid 20+10 μg , CTX: Cefotaxime 30 μg , CRO: Ceftriaxone 30 μg , CAZ: Ceftazidime 30 μg , IMP: Imipenem 10 μg , CN: Gentamicin 15 μg , AK: Amikacin 30 μg , TM: Tobramycin 10 μg , TE: Tetracycline 30 UI , CIP: Ciprofloxacin 5 μg , LIV: Levofloxacin.
Numbers and percentages of gram-negative bacteria that were resistant to antimicrobials isolated from urine of outpatients infected with urinary tract infection
| 14(35.9) | 25(64.1) | 10(33.3) | 20(66.7) | 7(38.9) | 11(61.1) | |
| 9(37.5) | 15(62.5) | 11(42.3) | 15(57.7) | 6(60) | 4(40) | |
| 8(38) | 13(62) | 9(45) | 11(55) | 5(62.5) | 3(37.5) | |
| 12(54.5) | 10(45.5) | 10(43.4) | 13(56.6) | 6(75) | 2(25) | |
| 8(36.3) | 14(63.7) | 10(47.6) | 11(52.4) | 4(44.4) | 5(55.6) | |
| 0(0.0) | 0(0.0) | 00(0.0) | 2(100) | 00(0.0) | 00(0.0) | |
| 7(38.8) | 11(61.2) | 10(52.6) | 9(47.4) | 3(42.8) | 4(57.2) | |
| 8(57.1) | 6(42.9) | 4(44.4) | 5(55.6) | 2(40) | 3(60) | |
| 5(33.3) | 10(66.7) | 4(33.3) | 8(66.7) | 5(55.5) | 4(44.5) | |
| 7(36.8) | 12(63.2) | 11(61.1) | 7(38.9) | 2(25) | 6(75) | |
| 6(40) | 9(60) | 6(37.5) | 10(62.5) | 2(28.5) | 5(71.5) | |
| 8(44.4) | 10(55.6) | 9(64.2) | 5(35.8) | 3(42.8) | 4(57.2) | |
WKD: Without kidney disease, CKD: Chronic kidney disease, AX: Amoxicillin 25 μg , AMC: Amoxicillin + Clavulanic acid 20+10 μg , CTX: Cefotaxime 30 μg , CRO: Ceftriaxone 30 μg , CAZ: Ceftazidime 30 μg , IMP: Imipenem 10 μg , CN: Gentamicin 15 μg , AK: Amikacin 30 μg , TM: Tobramycin 10 μg , TE: Tetracycline 30 UI , CIP: Ciprofloxacin 5 μg , LIV: Levofloxacin.
Figure 4.MDR, XDR and PDR gram-negative bacteria isolated from outpatients infected with urinary tract infection. MDR: Multidrug resistance; XDR: Extensive drug resistance; PDR: Pandrug resistance, WKD: Without kidney disease, CKD: Chronic kidney disease.
Numbers and percentages of MDR, XDR and PDR gram-negative bacteria isolated from urine of outpatients infected with urinary tract infection
| MDR | 15 (51.7) | 19 (95) | 34(69.3) |
| XDR | 0(0.0) | 1(5) | 1(2) |
| PDR | 0(0.0) | 0(0.0) | 0(0.0) |
| MDR | 18(100) | 14(82.3) | 32(91.4) |
| XDR | 0(0.0) | 2(11.7) | 2(5.7) |
| PDR | 0(0.0) | 1(5.8) | 1(2.8) |
| MDR | 8(100) | 8(80) | 16(88.8) |
| XDR | 0(0.0) | 2(20) | 2(11.1) |
| PDR | 0(0.0) | 0(0.0) | 0(0.0) |
| MDR | 1(33.3) | 8(88.8) | 9(75) |
| XDR | 0(0.0) | 0(0.0) | 0(0.0) |
| PDR | 0(0.0) | 0(0.0) | 0(0.0) |
| MDR | 0(0.0) | 3(50) | 3(37.5) |
| XDR | 0(0.0) | 0(0.0) | 0(0.0) |
| PDR | 0(0.0) | 0(0.0) | 0(0.0) |
| MDR | 0(0.0) | 2(50) | 2(50) |
| XDR | 0(0.0) | 0(0.0) | 0(0.0) |
| PDR | 0(0.0) | 0(0.0) | 0(0.0) |
MDR: Multidrug resistance; XDR: Extensive drug resistance; PDR: Pandrug resistance. WKD: Without kidney disease, CKD: Chronic kidney disease.
Figure 5.Prevalence of extended spectrum beta-lactamase-producing gram-negative bacteria isolated from outpatients infected with urinary tract infection. WKD: Without kidney disease, CKD: Chronic kidney disease.
Figure 6.Positive result of ESBL-producing K. pneumoniae by DDST on Muller Hinton agar surface after 24 hr of incubation at 37°C. CRO: Ceftriaxone 30 μg., CTX: Cefotaxime 30 μg, CAZ: Ceftazidime 30 μg AMC: Amoxi/Clavulanic acid 30 μg.
Numbers and percentages of phenotypic results of extended-spectrum β-lactamase -producing gram-negative bacteria isolated from outpatients infected with urinary tract infection
| ESBL | 2(6.9) | 6(30) | 9(18.3) | 0.0497 |
| Non-ESBL | 27(93.1) | 14(70) | 40(81.7) | |
| Total | 29(100) | 20(100) | 49(100) | |
| ESBL | 3(16.6) | 10(58.8) | 13(37.1) | 0.0153 |
| Non-ESBL | 15(83.4) | 7(41.2) | 22(62.9) | |
| Total | 18(100) | 17(100) | 35(100) | |
| ESBL | 1(12.5) | 3(30) | 4(22.2) | 0.5882 |
| Non-ESBL | 7(87.5) | 7(70) | 14(77.3) | |
| Total | 8(100) | 10(100) | 18(100) | |
| ESBL | 0(0.0) | 1(11.1) | 1(8.3) | 1.0000 |
| Non-ESBL | 3(100) | 8(88.9) | 11(91.7) | |
| Total | 3(100) | 9(100) | 12(100) | |
| ESBL | 0(0.0) | 1(16.6) | 1(12.5) | 1.0000 |
| Non-ESBL | 2(100) | 5(83.4) | 7(87.5) | |
| Total | 2(100) | 6(100) | 8(100) | |
| ESBL | 0(0.0) | 0(0.0) | 0(0.0) | - |
| Non-ESBL | 0(0.0) | 4(100) | 4(100) | |
| Total | 0(0.0) | 4(100) | 4(100) | |
ESBL: Extended-spectrum β-lactamase -producing bacteria, WKD: Without kidney disease, CKD: Chronic kidney disease, P-value
: Comparison between WKD and CKD.
Figure 7.Distribution of ESBLs-genes of 126 gram-negative bacteria isolated from outpatients infected with urinary tract infections. WKD: Without kidney disease, CKD: Chronic kidney disease.
Numbers and percentages of ESBLs-genes in 126 gram-negative bacterial isolates from outpatients infected with urinary tract infections
| 9(31) | 13(65) | 21(42.8) | |
| 8(27.5) | 10(50) | 18(36.7) | |
| 7(24.1) | 12(60) | 19(38.7) | |
| 15(83.3) | 15(88.2) | 30(85.7) | |
| 10(55.5) | 13(76.4) | 23(65.7) | |
| 11(61.1) | 13(6.4) | 24(68.5) | |
| 0 | 1(10) | 1(5.5) | |
| 0 | 1(10) | 1(5.5) | |
| 0 | 1(10) | 1(5.5) | |
| 1(33.3) | 5(55.5) | 6(50) | |
| 1(33.3) | 3(33.3) | 4(33.3) | |
| 1(33.3) | 4(44.4) | 5(41.6) | |
| 1(50) | 3(50) | 4(50) | |
| 0(0.0) | 2(33.3) | 2(25) | |
| 0(0.0) | 2(33.3) | 2(25) | |
| 0(0.0) | 2(50) | 2(50) | |
| 0(0.0) | 1(25) | 1(25) | |
| 0(0.0) | 1(25) | 1(25) | |
WKD: Without kidney disease, CKD: Chronic kidney disease
Figure 8.PCR amplification of Bla-TEM gene in E. coli isolates from urine of outpatients infected with UTI with chronic kidney disease showing positive results at 643 bp. L: DNA size marker. 1–10: number of isolates.
Figure 10.PCR amplification of Bla-CTXM gene in C. freundii isolates from urine of outpatients infected with UTI with chronic kidney disease showing positive results at 766 bp. L: DNA size marker. 1–10: number of isolates